

# Postpartum HIV Care Engagement: Challenges and Clinical Considerations

Florence Momplaisir, MD MSHP FACP
Assistant Professor
Perelman School of Medicine
Division of Infectious Diseases



#### Learning Objectives

- Describe existing racial disparities in perinatal HIV transmission in the U.S.
- Discuss barriers and facilitators to HIV care engagement in the postpartum period
- Discuss new breastfeeding guidelines in the U.S. and understand implications for infant feeding counseling




#### Disclosures

No conflicts of interest

# Epidemiology


# Global Perspective

- 37.9 million people with HIV worldwide
  - 55% WOMEN
- 1.7 million people became infected with HIV in 2018
  - Women account for 20%-25% of incident in Europe and the U.S.
  - Majority of new cases in Africa (up to 79% in S. and Eastern Africa)
- Globally, 1.3 million women with HIV become pregnant each year




# HIV Diagnoses in the U.S., 2005-2014








# HIV Diagnoses by Among Cis-gender Southeast Regional Conference 2023 Women by Race and Ethnicity, 2005-2014



#### HIV incidence in Pregnancy & Postpartum







# Pediatric Considerations



## **Achieving Elimination of Perinatal HIV**

Diagnosis Rate and EAPC of Perinatally Acquired HIV Among Persons Born in the United States, by Year of Birth, Overall, and by Mother's Race and Ethnicity, 2010–2019

| Diagnosis Rate <sup>a</sup>  |     |      |      |      |      |      |      |      |      |      |      |                             |
|------------------------------|-----|------|------|------|------|------|------|------|------|------|------|-----------------------------|
| Race and ethnici             | ty/ | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | EAPC <sup>b</sup> (95% CI)  |
| Black/African<br>American    |     | 6.6  | 6.5  | 8.1  | 4.5  | 5.3  | 5.3  | 5.4  | 4.6  | 3.3  | 3.1  | 7.67 (-11.30 to<br>-3.89)   |
| Hispanic/Latino <sup>C</sup> |     | 1.7  | 1.6  | 1.0  | 1.0  | 0.7  | 0.9  | 1.1  | 0.8  | 0.8  | 0.8  | -8.42 (-14.77 to<br>-1.60)  |
| White                        |     | 0.4  | 0.0  | 0.3  | 0.2  | 0.2  | 0.3  | 0.1  | 0.3  | 0.3  | 0.3  | 0.19 (-8.75 to<br>10.02)    |
| Other                        |     | 3.6  | 2.9  | 2.4  | 2.4  | 2.0  | 1.7  | 1.6  | 1.6  | 1.4  | 0.8  | -12.05 (-19.43<br>to -4.00) |
| Total                        |     | 1.9  | 1.6  | 1.8  | 1.2  | 1.2  | 1.3  | 1.2  | 1.2  | 0.9  | 0.9  | -7.25 (-10.05 to<br>-4.35)  |

Have we achieved elimination of Perinatal HIV in the U.S.?

Diagnosis rates are per 100 000 live births. CI, confidence interval.

- a National HIV Surveillance System.
- b Estimated annual percent change and 95% confidence intervals estimated using Poisson regression models.
- c Hispanic/Latino persons can be of any race; other race includes American Indian/Alaska Native, Asian, Native Hawaiian/other Pacific Islander, and multiracial persons.



# Risk for Pediatric Infections During Pregnancy and the Postpartum Period



Infection risk w/ no intervention:

5-10%

10-20%

5-20%

In the absence of intervention, breastfeeding accounts for ~ 40% of infant HIV infections

# HIV Testing During Pregnancy Southeast Regional Conference 2023

Test all pregnant persons at the initiation of care

Re-test during the 3rd trimester


Rapid screening during labor if status unknown

In those at high-risk, teach about signs/ symptoms of Acute Retroviral Syndrome (ARS)






# U.S. Recommended Virologic Testing Schedules for Infants Exposed to HIV by Perinatal HIV Transmission Risk







# ART has <u>drastically</u> reduced perinatal HIV transmission



Prenatal Maternal Antiretroviral Therapy

Source: Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 pregnant women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-94.





# Differences between adolescents who acquire HIV perinatally vs during adolescence (cont'd)

| Period HIV Was Acquired   |   |  |  |  |  |  |  |
|---|---|--|--|--|--|--|--|
| Perinatal   | Adolescence   |  |  |  |  |  |  |
| Primary caregiver knows HIV status     Caregiver needs to disclose status     to adolescent if they do not already     know     Similarities: Coping with process | Coping with new diagnosis Coping with disclosure to primary caregiver Coping with disclosure to partner of disclosing to family and peers   |  |  |  |  |  |  |
| Caregivers know adolescent's HIV-<br>status and offer support   | <ul> <li>Support system for HIV depends<br/>on disclosure</li> </ul>  |  |  |  |  |  |  |
| May be unstable if orphaned   | <ul> <li>May have few resources if has<br/>left home</li> </ul>   |  |  |  |  |  |  |
| Often on ART for many years   | <ul> <li>May not be receiving ART yet</li> </ul>  |  |  |  |  |  |  |
| Similarities: Adherence challenges in childhood and adolescence   |   |  |  |  |  |  |  |
| Less likely to be blamed; considered     "innocent"     Similarities: I   | More likely to be blamed<br>because of "irresponsible"<br>behavior      ace stigma  |  |  |  |  |  |  |
|   | Perinatal  Primary caregiver knows HIV status  Caregiver needs to disclose status to adolescent if they do not already know  Similarities: Coping with process of Caregivers know adolescent's HIV-status and offer support  May be unstable if orphaned  Often on ART for many years  Similarities: Adherence challenged |  |  |  |  |  |  |

World Health Organization. 2010. Lam PK, et al. J Int AIDS Soc. 2017;20(Buppl 3):21506.



# Maternal Considerations

# Treatment Recommendations in Pregnancy

- ART is recommended for all pregnant people with HIV, regardless of CD4 count and HIV RNA
- If pregnant person's viral load is suppressed, continue current regimen
- Preferred regimens:
  - Backbone NRTI
    - Tenofovir DF/emtricitabine or abacavir/lamivudine (if HLA-B\*5701 not present)
    - TAF/FTC recommended as alternative
  - Addition of either
    - INSTI (dolutegravir or raltegravir)
    - Boosted PI (atazanavir/ritonavir qday or darunavir/ritonavir twice a day
- Assess benefits for PrEP if HIV negative





#### PREVENTION OPPORTUNITIES

Primary HIV prevention for Women and girls

Adequate preconception care and family planning services

Accessible, affordable and adequate prenatal care

Universal prenatal HIV testing (routine opt-out)

Providing ART to all eligible

Delivery via C-section scheduled if maternal VL > 1000

Continued engagement in HIV care postpartum

Retention and viral suppression, Y1 and Y2 postpartum





#### Case

Called to consult on a young African American woman diagnosed with HIV at L&D

Her previous HIV test was negative in the 1<sup>st</sup> trimester, which was also her 1<sup>st</sup> and last prenatal visit

Presented in labor, test had resulted right before delivery

Overwhelmed and anxious



#### Case



#### Multi-layered issues:

- HIV- disclosure, stigma, anxiety
- Additional mental illness (depression, PTSD)
- Substance use, baby removed from custody
- SES, no income
- Postpartum care challenges: visits for HIV, primary care and mental health at separate locations







Lost to care after delivery

Returned to HIV care with subsequent pregnancy 1 year later, not on ART

Re-established HIV care during pregnancy

Lost to care and died about 18 months post delivery



# **Postpartum Period**



onal Conference 2023

Clinical Infectious Diseases Advance Access published August 30, 2015

MAJOR ARTICLE

HIV/AIDS

# Postpartum Engagement in HIV Care: An Important Predictor of Long-term Retention in Care and Viral Suppression

Joëlla W. Adams, Kathleen A. Brady, Yvonne L. Michael, Baligh R. Yehia, 4 and Florence M. Momplaisir

<sup>1</sup>AIDS Activities Coordinating Office, Philadelphia Department of Public Health, <sup>2</sup>Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, <sup>3</sup>Department of Epidemiology, Drexel University School of Public Health, <sup>4</sup>Leonard Davis Institute of Health Economics, University of Pennsylvania, and <sup>5</sup>Division of Infectious Diseases and HIV Medicine, Drexel University School of Medicine, Philadelphia, Pennsylvania



### **Specific Aims**



- 1) Describe aspects of the HIV care continuum, specifically retention and viral suppression, of women with HIV up to two years after delivery
- 2) Evaluate factors associated with these outcomes






#### Methods

- Data Sources
  - Philadelphia Enhanced Perinatal Surveillance
  - Philadelphia Enhanced HIV/AIDS Reporting System
- Study Population
  - Women with HIV who delivered in Philadelphia between 2005-2011





# Care Continuum Postpartum (2005-2011)





# Role of Immediate Postpartum Care AETC AIDS Education & Conference 2023

Engagement

| HIV Care         |
|------------------|
| Engagement       |
| Within 3 Months  |
| Postpartum (y/n) |


| Retention in Care, 1 Year AOR 95% CI       | Retention in Care, 2<br>Years            |  |  |  |  |
|--|--|--|--|--|--|
|  | AOR 95% CI                               |  |  |  |  |
| 11.1 (7.6-16.3)                            | 6.2 (4.0-9.5)                            |  |  |  |  |
| Viral Suppression, 1<br>Year<br>AOR 95% CI | Viral Suppression, 2<br>Years AOR 95% CI |  |  |  |  |
| 2.6 (1.8-3.7)                              | 1.4 (1.0-1.9)                            |  |  |  |  |

Models adjusted for age, race, substance use, timing of HIV diagnosis, number of previous pregnancies with HIV, ART use, adequacy of prenatal care and year of delivery





#### Care Continuum in the Southern US








### Decline in Perinatal Transmission of HIV is a Success but Less Emphasis Placed on Women Postpartum

Decline in the rate of Mother-to-Child Transmission of HIV









"So many of these tragic deaths were related to social-economic status," says one doctor.

BY HOLLY OTTERBEIN | JUNE 17, 2015 AT 8:39 AM



#### PHILADELPHIA DEPARTMENT OF PUBLIC HEALTH MEDICAL EXAMINER'S OFFICE

James W. Buehler, MD - Commissioner


Sam P. Gulino, MD - Chief Medical Examiner


- Philadelphia Maternal Mortality Review, 2010-2012
- Maternal mortality rate is 27.4 deaths per 100,000 births, 50% higher than national average
- 56% were black
- The prevalence of HIV was 16 times higher among these women than women living in Philadelphia





# Maternal Mortality, 4 states (2008-2014)









## ACOG Recommendations for Postpartum care




Figure 1. Proposed paradigm shift for postpartum visits. The American College of Obstetricians and Gynecologists' Presidential Task Force on Redefining the Postpartum Visit and the Committee on Obstetric Practice propose shifting the paradigm for postpartum care from a single 6-week visit (bottom) to a postpartum process (top). Abbreviations: BP, blood pressure; f/u, follow-up. <-





### Summary

- Women with HIV are falling sharply out of HIV care within 3 months of delivery
- Those who disengage in HIV care postpartum are less likely to be retained and suppressed up to 2 years after delivery
- Grave consequences for maternal outcomes
- Need to understand barriers to sustained engagement







- Mixed-methods
- In-depth interviews to evaluate attitudes and beliefs influencing engagement in HIV care in the postpartum period
- Structural factors associated with maternal HIV outcomes, measured at the neighborhood level



Outcomes



### Stigma

"It's hard to tell someone but it's hard. And it's where I'm at, because I want to talk to him, but when I hear him talk about someone he knows who has it, or about AIDS, it's like, if this is how you really feel, then if I tell you, how will you feel about me? If you feel that towards somebody else. That's where I'm at, so...why say anything about it..."





### Depression

"It was like I am pregnant, shelter, and I am still working (...). Now, I am going to have the baby which is more stress, more mental problems. So it was just a whole lot on my last daughter. It was like, I didn't want to do nothing. I didn't want to go outside [to get food]. I didn't want to go nowhere."





# Commitment to Pediatric Health

"I just think about the baby. I want to take this [medicine] for the baby. If I wasn't suppressed, I wouldn't take the medicine to be honest. The baby is like, I've got two lives, not just mine. So it was like, what is more important? My baby."





# Peer Mentor Support

"...it's harder to talk about how I'm feeling so I figured if there's a community of women that has it [HIV], I'd be easier and open to express my feelings. Sometimes I'm like who can I talk to? I can't talk to my mom, I can't talk to my sister because they don't know, they don't experience it."





# Implication for Intervention Development

Capitalize on women's motivation to keep their infant healthy to leverage retention in care postpartum

Address depressive symptoms during pregnancy and the postpartum period

Role of family and social support

Taking into account social determinants that negatively impact viral suppression











# Breastfeeding

## Mechanisms of Perinatal HIV transmission



HIV-1 transmission occurs through the placenta or by swallowing large amounts of infected biological fluids such as the amniotic fluid during gestation, or blood and vaginal secretions during delivery and milk (predominantly) during breastfeeding



In both the placenta and the gastrointestinal tract, viral transmission may rely on breaches of the tissue, on direct infection of cells or transcytosis of cell-associated virus.





# Weighing Risks and Benefits



#### Risk of breastmilk

- Risk of HIV transmission
- Risk of more infant prophylaxis

#### Benefit of breastmilk

- Maternal antibody
- No risk of unclean water







# What is the Actual Risk of Transmission with ART

- We don't have robust data from "high income" countries
- PROMISE study (Southern Africa)
  - Maternal ART vs. infant prophylaxis until 18 months or end of breastfeeding → 0.3% at 6mo and 0.7% at 12mo in maternal ART arm
- Increased viral load in mom is associated with transmission to infants
  - However, we don't know the "safe threshold" for viral load
  - Cases of transmission even when the maternal HIV viral load was undetectable



### Reminder on U=U



#### **NEWS RELEASES**

Media Advisory

Thursday, January 10, 2019

The science is clear: with HIV, undetectable equals untransmittable

NIH officials discuss scientific evidence and principles underlying the U=U concept.

- "Overwhelming" evidence
  - HPTN 052: >1700 couples
  - PARTNER 1: 58,000 condomless sex acts
  - Opposites Attract: 343 MSM couples
  - PARTNER 2: 77,000 condomless sex acts in MSM couples

- We don't have the same quantity of data for breastfeeding
- Hopefully will get these data that "low income" countries guidelines recommend lifelong ART
- But in the end, it will take longer (birth is a less common event than sex!)





# Social implications

- A qualitative study of mothers living with HIV in Canada found that infant feeding is a social, cultural, and emotional issue, often underpinned by HIV-related stigma.
- Some women fear that not breastfeeding will lead to disclosure of their HIV status.
- Multiple case series showing that women with HIV are breastfeeding in resource rich settings.





#### Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States

#### **Panel's Recommendations**

- People with HIV should receive evidence-based, patient-centered counseling to support shared decision-making
  about infant feeding. Counseling about infant feeding should begin prior to conception or as early as possible in
  pregnancy; information about and plans for infant feeding should be reviewed throughout pregnancy and again after
  delivery (AIII). During counseling, people should be informed that—
  - Replacement feeding with properly prepared formula or pasteurized donor human milk from a milk bank eliminates the risk of postnatal HIV transmission to the infant (AI).
  - Achieving and maintaining viral suppression through antiretroviral therapy (ART) during pregnancy and postpartum decreases breastfeeding transmission risk to less than 1%, but not zero (AI).
- Replacement feeding with formula or banked pasteurized donor human milk is recommended to eliminate the risk of HIV transmission through breastfeeding when people with HIV are not on ART and/or do not have a suppressed viral load during pregnancy (at a minimum throughout the third trimester), as well as at delivery (AI).
- Individuals with HIV who are on ART with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision (AIII).
- Individuals with HIV who choose to formula feed should be supported in this decision. Providers should ask about potential barriers to formula feeding and explore ways to address them (AIII).
- Engaging Child Protective Services or similar agencies is not an appropriate response to the infant feeding choices of an individual with HIV (AIII)



# Policy Implications



- Supportive, nonjudgmental communication (including assessment of desire to breastfeed)
- Increasing awareness of poor postpartum care retention
- Support effective transition in care from pregnancy to postpartum
- Refine existing care coordination resources to understand and address unique needs of pregnant/postpartum women with HIV
- Organize plans and procedures for communication across disciplines and care settings
- Investing in health information exchange of electronic health records to overcome fragmentation of prenatal/postnatal, HIV, primary, and pediatric care



# Acknowledgment



#### **Funding:**

- Harold Amos Medical Faculty Development Program (AMFDP) from the Robert Wood Johnson Foundation, 73319
- National Institute on Minority Health and Health Disparities, R01MD013558
- HRSA Supplemental Funds, Ryan White Part D Services to Women, Infants, Children and Youth, H12HA248470601
- IMPAACT Early Career Mentored Research Award, UM1AI068632, UM1AI068616
- Mary Dewitt Pettit Fellowship Funds, Drexel College of Medicine
- Penn Mental Health AIDS Research Center Pilot Grant/National Institute of Mental Health, P30MH097488

Mentors: John Jemmott, Ana Diez Roux

Research team: Hervette Nkwihoreze, Fatemeh Ghadimi, Philadelphia Department of

Public Health

Research participants



# Thank You!



